Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | CEL | P19835 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | TLR4 | O00206 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7736601 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CELCNR2 | |
| SCHEMBL7736605 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CELCNR2 | |
| SCHEMBL16501541 | 0.96 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3CELKDM1A | |
| SCHEMBL7736265 | 0.95 | CTSL (0.37) | SLC6A2SLC6A4SLC6A3CELCTSL | |
| SCHEMBL7736269 | 0.95 | CTSL (0.37) | SLC6A2SLC6A4SLC6A3CELCTSL | |
| SCHEMBL7736263 | 0.95 | CTSL (0.37) | SLC6A2SLC6A4SLC6A3CELCTSL | |
| SCHEMBL9399040 | 0.95 | CNR2 (0.35) | SLC6A2SLC6A4SLC6A3CELCNR2 | |
| SCHEMBL9399033 | 0.95 | CNR2 (0.35) | SLC6A2SLC6A4SLC6A3CELCNR2 | |
| SCHEMBL9399028 | 0.95 | CNR2 (0.35) | SLC6A2SLC6A4SLC6A3CELCNR2 | |
| SCHEMBL15355216 | 0.92 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CELCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458433-B1 | ISOTOPE REPLACEMENT; OPTICAL DISPLAY | CHISSO CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020038858-A1 | Isotope replacement; optical display | JNC CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
| EP-0949232-A1 | DIFLUOROPHENYL DERIVATIVES, LIQUID-CRYSTAL COMPOUNDS, AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5346647-A | Cyclohexane compounds used in liquid crystalline mixtures | HOFFMANN-LA ROCHE INC. (US) | 1994-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038858-A1 | Isotope replacement; optical display | IRS1, FES, IK | SLC6A2 3221/4885SLC6A4 2666/4885SLC6A3 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.